NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has agreed to work with MD Anderson spinout ApoCell to make its ApoStream liquid biopsy technology available to biotech and pharmaceutical companies.

ApoStream is a platform for the detection, isolation, and capture of circulating tumor cells (or other rare cells), and does not require the use of labels or antibodies.